Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

193
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
193
Inhaled Medications01:23

Inhaled Medications

248
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
248
Drug Delivery: Miscellaneous Routes01:22

Drug Delivery: Miscellaneous Routes

335
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection,  and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs...
335
Drug Delivery: Enteral Route01:18

Drug Delivery: Enteral Route

410
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
410
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

2.5K
Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
2.5K
  1. Home
  3. Research Domains
  5. Indigenous Studies
  7. Te Hauora Me Te Oranga O Te Māori (māori Health And Wellbeing)
  9. Te Whaikaha Me Te Māori (māori And Disability)
  11. Pulmonary Delivery Of Magnolol-loaded Nanostructured Lipid Carriers For Copd Treatment.
  1. Home
  3. Research Domains
  5. Indigenous Studies
  7. Te Hauora Me Te Oranga O Te Māori (māori Health And Wellbeing)
  9. Te Whaikaha Me Te Māori (māori And Disability)
  11. Pulmonary Delivery Of Magnolol-loaded Nanostructured Lipid Carriers For Copd Treatment.

Related Experiment Video

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K

Pulmonary delivery of magnolol-loaded nanostructured lipid carriers for COPD treatment.

Bei Jia1, Jiachen He1, Ying Zhang2

  • 1School of Chinese Materia Medica, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; Engineering Research Center of Modern Chinese Medicine Discovery and Preparation Technique, Ministry of Education, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China; State Key Laboratory of Component-based Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China.

International Journal of Pharmaceutics
|July 25, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

This study developed Magnolol-loaded nanostructured lipid carriers (MA-NLC) for pulmonary delivery to treat chronic obstructive pulmonary disease (COPD). MA-NLC effectively reduced inflammation and oxidative stress in COPD models, showing promise for improved COPD management.

Keywords:
Lung targetingNanostructured lipid carriersPharmacodynamicsPulmonary administration

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.6K
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.3K

Related Experiment Videos

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

8.9K
Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

40.6K
Intratracheal Administration of Dry Powder Formulation in Mice
07:55

Intratracheal Administration of Dry Powder Formulation in Mice

Published on: July 25, 2020

10.3K

Area of Science:

  • Nanotechnology
  • Pharmacology
  • Pulmonary Medicine

Background:

  • Chronic obstructive pulmonary disease (COPD) is a major global health issue with high mortality.
  • Magnolol (MA) possesses anti-inflammatory and antioxidant properties beneficial for COPD but suffers from poor solubility and bioavailability.
  • Existing delivery methods for MA present significant limitations for effective COPD treatment.

Purpose of the Study:

  • To develop and characterize Magnolol-loaded nanostructured lipid carriers (MA-NLC) for pulmonary administration.
  • To evaluate the efficacy of MA-NLC in managing COPD by targeting lung tissues and improving MA bioavailability.
  • To assess the potential of MA-NLC as a novel therapeutic strategy for COPD.

Main Methods:

  • MA-NLC were prepared using emulsification and solvent evaporation techniques.
  • Characterization included particle size, polydispersity index, zeta potential, and fine particle fraction analysis.
  • The therapeutic efficacy was evaluated in COPD models, focusing on pulmonary delivery and modulation of inflammatory and oxidative stress markers.

    • Main Results:

    • MA-NLC exhibited optimal physicochemical properties with a particle size of approximately 19.67 nm and a high fine particle fraction (68.90%).
    • Pulmonary delivery of MA-NLC demonstrated targeted delivery to lung tissues, slow drug release, and enhanced bioavailability compared to oral MA.
    • MA-NLC effectively regulated key inflammatory and oxidative stress markers in COPD models, indicating significant therapeutic potential.

    Conclusions:

    • MA-NLC represent a promising nanocarrier system for the pulmonary delivery of Magnolol.
    • This formulation overcomes the limitations of MA's poor solubility and bioavailability, offering an improved therapeutic strategy for COPD.
    • MA-NLC holds potential as a safe and effective platform for managing chronic obstructive pulmonary disease.